Antitumor benzothiazoles. 7. Synthesis of 2-(4-acylaminophenyl)benzothiazoles and investigations into the role of acetylation in the antitumor activities of the parent amines

被引:132
作者
Chua, MS
Shi, DF
Wrigley, S
Bradshaw, TD
Hutchinson, I
Shaw, PN
Barrett, DA
Stanley, LA
Stevens, MFG [1 ]
机构
[1] Univ Nottingham, Sch Pharmaceut Sci, Canc Res Labs, Nottingham NG7 2RD, England
[2] De Montfort Univ, Dept Pharmaceut Sci, Leicester LE1 9BH, Leics, England
关键词
D O I
10.1021/jm981076x
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
2-(4-Aminophenyl)benzothiazoles display potent and selective antitumor activity against inter alia breast, ovarian, colon, and renal cell lines, but their mechanism of action, though yet to be defined, may be novel. Metabolism is suspected to play a central role in the mode of action of these benzothiazoles since drug uptake and biotransformation were observed in sensitive cell lines (e.g., breast MCF-7 and MDA 468 cells) in vitro, whereas insensitive cell lines (e.g., prostate PC 3 cells) showed negligible uptake and biotransformation. N-Acyl derivatives of the arylamines have been synthesized, and in vitro studies confirm N-acetylation and oxidation as the main metabolic transformations of 2-(4-aminophenyl)benzothiazoles, with the predominant process being dictated by the nature of the 3'-substituent. The prototype amine 3 underwent mainly N-acetylation in vitro, while 3'-substituted analogues 4 and 5 were primarily oxidized. N-Acetylation of 4 to 11 exerts a drastic dyschemotherapeutic effect in vitro, but acetylation of the halogeno congeners 5-7 gave acetylamines 12-14 which substantially retain selective antitumor activity. In vivo pharmacokinetic studies in rats confirmed rapid and exclusive N-acetylation of the 3'-methyl analogue 4, but less acetylation with the 3'-chloro analogue 5. Distinct expression patterns of N-acetyltransferase NAT1 and NAT2 have been demonstrated in our panel of cell lines.
引用
收藏
页码:381 / 392
页数:12
相关论文
共 24 条
  • [1] Structure-activity relationships of the 7-substituents of 5,4′-diamino-6,8,3:-trifluoroflavone, a potent antitumor agent
    Akama, T
    Ishida, H
    Kimura, U
    Gomi, K
    Saito, H
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (12) : 2056 - 2067
  • [2] BADAWI AF, 1995, CANCER RES, V55, P5230
  • [3] BAMBERGER E, 1899, LIEBIGS ANN CHEM, V305, P339
  • [4] METABOLIC POLYMORPHISMS AFFECTING ACTIVATION OF TOXIC AND MUTAGENIC ARYLAMINES
    BOCK, KW
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (06) : 223 - 226
  • [5] SOME PRACTICAL CONSIDERATIONS AND APPLICATIONS OF THE NATIONAL-CANCER-INSTITUTE IN-VITRO ANTICANCER DRUG DISCOVERY SCREEN
    BOYD, MR
    PAULI, KD
    [J]. DRUG DEVELOPMENT RESEARCH, 1995, 34 (02) : 91 - 109
  • [6] Bradshaw T. D., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P217
  • [7] 2-(4-aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity
    Bradshaw, TD
    Wrigley, S
    Shi, DF
    Schultz, RJ
    Paull, KD
    Stevens, MFG
    [J]. BRITISH JOURNAL OF CANCER, 1998, 77 (05) : 745 - 752
  • [8] Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo
    Bradshaw, TD
    Schultz, RJ
    Paull, KD
    Kelland, L
    Wilson, A
    Garner, C
    Fiebig, HH
    Wrigley, S
    Stevens, MFG
    [J]. BRITISH JOURNAL OF CANCER, 1998, 78 (04) : 421 - 429
  • [9] DOUBLE JA, COMMUNICATION
  • [10] ERBER S, 1991, ANTI-CANCER DRUG DES, V6, P417